The abstract is read at the publisher; the summary is JClub's.
In nonmetastatic dMMR/MSI-H locally advanced lower rectal cancer, 13/13 per-protocol patients achieved clinical complete response and entered watch-and-wait after neoadjuvant sintilimab.
- Why it matters: Neoadjuvant PD-1 blockade can shrink tumors, but clinicians still lack clear evidence on how to assess response reliably and whether watch-and-wait is safe.
- What they did: In a single-arm phase 2 trial at two Chinese centers, patients received six cycles of sintilimab 200 mg every 3 weeks, then underwent multimodal assessment (endoscopy, MRI/CT, CEA, exams, and transrectal ultrasound-guided biopsy).
- The result: With median follow-up 37.7 months in the intention-to-treat population, no local recurrence or distant metastasis occurred and estimated 1-year disease-free and overall survival were both 93.3% (95% CI 68.1%-99.8%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.